Off-Label Gabapentin Use Up Despite 'Dearth of Evidence'

The drug may be prescribed with sedating medications even after a 2019 warning from the FDA about such combinations.

Related Keywords

Michigan ,United States ,Ann Arbor ,Michaele Johansen ,Donovant Maust , ,Expenditure Panel ,Drug Administration ,Ann Arbor Va Center ,National Institute On Drug Abuse ,Clinical Management Research ,University Of Michigan ,Expenditure Panel Survey ,Grant Family Medicine ,Medical Expenditure Panel Survey ,National Institute ,Pain Management ,Back Pain ,Spain ,Fibromyalgia ,Chronic Pain ,Neuropathic Pain ,Central Nervous System ,Ns ,Addiction ,Multiple Sclerosis Ms ,S Multiple Sclerosis ,Diabetic Peripheral Neuropathy ,Opioids ,Drug Abuse ,Neuromuscular Blocking Drug ,Muscle Relaxant ,Neuromuscular Blocking Agent ,Peripheral Neuropathy ,Postherpetic Neuralgia ,Diabetic Neuropathy ,Diabetic Neuropathies ,